Myriam Riek

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition

Ashok Rakhit, Michael Pantze, Scott Fettner et al. · European Journal of Clinical Pharmacology · 2007 · 120 citations

Pharmacokinetic Modeling, Cyp3a4 Inhibition, Erlotinib Pharmacokinetics +8

Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry

Cem Gabay, Myriam Riek, Almut Scherer et al. · Lara D. Veeken · 2015 · 94 citations

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

Jie Ling, Scott Fettner, Bert L. Lum et al. · Anti-Cancer Drugs · 2008 · 86 citations

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study

Cem Gabay, Myriam Riek, Merete Lund Hetland et al. · Annals of the Rheumatic Diseases · 2015 · 70 citations · Full text

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers

Christophe Schmitt, Myriam Riek, Katie Winters et al. · Archives of Drug Information · 2009 · 67 citations · Full text

Clinical Symptoms, Pharmacotherapy, Antiviral Drug +19